DFCI 00-01 included a cohort of newly diagnosed ALL patients who experienced hypersensitivity to E. coli asparaginase and were switched to IM ERW for all remaining courses of asparaginase therapy (35). The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.